Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oral Dis ; 24(4): 580-590, 2018 May.
Article in English | MEDLINE | ID: mdl-29197137

ABSTRACT

OBJECTIVE: To characterize the immunohistopathological features of oral chronic graft-versus-host disease (cGVHD), and the impact of topical immunomodulatory therapy on the infiltrating cells. MATERIAL AND METHODS: Paired oral cGVHD biopsies obtained before (n = 12) and 1 month after treatment (n = 12) with topical dexamethasone (n = 8) or tacrolimus (n = 4) were characterized by immunohistochemistry using a panel of CD1a, CD3, CD4, CD8, CD20, CD31, CD62E, CD103, CD163, c-kit, and FoxP3. Controls included acute GVHD (aGVHD; n = 3), oral lichen planus (OLP; n = 5), and normal tissues (n = 5). RESULTS: Oral cGVHD specimens prior to treatment were mainly characterized by basal cell squamatization, lichenoid inflammation, sclerosis, apoptosis, and lymphocytic exocytosis. The infiltrating cells in oral cGVHD primarily consisted of CD3+ , CD4+ , CD8+ , CD103+ , CD163+ , and FoxP3+ cells, which were higher than in normal tissues. Topical dexamethasone or tacrolimus reduced neutrophilic exocytosis, basal cell squamatization, and lichenoid inflammation in oral cGVHD, and dexamethasone reduced the number of CD4+ and CD103+ cells. CONCLUSION: The high expression of CD3, CD4, CD8, CD103, CD163, and FoxP3 confirms that oral cGVHD is largely T-cell-driven with macrophage participation. The impact of topical immunomodulatory therapy was variable, reducing histological inflammatory features, but with a weak clinicopathological correlation. Topical dexamethasone reduced the expression of CD4 and CD103, which may offer novel therapeutic targets.


Subject(s)
Antigens, CD/metabolism , Dexamethasone/therapeutic use , Glucocorticoids/therapeutic use , Graft vs Host Disease/drug therapy , Immunosuppressive Agents/therapeutic use , Mouth Diseases/drug therapy , Tacrolimus/therapeutic use , Administration, Topical , Adult , Aged , Female , Forkhead Transcription Factors/metabolism , Graft vs Host Disease/immunology , Graft vs Host Disease/pathology , Humans , Immunohistochemistry , Immunomodulation , Macrophages/metabolism , Male , Middle Aged , Mouth Diseases/immunology , Mouth Diseases/pathology , T-Lymphocytes/metabolism , Young Adult
2.
Oral Dis ; 23(6): 749-756, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27606832

ABSTRACT

Leprosy is a chronic infectious disease caused by Mycobacterium leprae, a bacillus that has a tropism for skin and peripheral nerves. Leprosy treatment is based on a multidrug therapy established by the World Health Organization in 1982 and, despite its widespread use, Brazil ranks second worldwide in numbers of cases. Oral involvement in leprosy has been poorly described in the literature, and few studies have shown that although the bacillus is found in mucosa, specific leprosy lesions are rare and affect patients with advanced stages of the disease. This review aimed to assess the literature on oral manifestations in leprosy and the aspects involving oral cavity in leprosy pathogenesis.


Subject(s)
Antibodies, Bacterial/analysis , Facial Dermatoses/microbiology , Leprosy/complications , Mouth Diseases/microbiology , Mycobacterium leprae/immunology , Biomarkers/analysis , Humans , Leprosy/diagnosis , Leprosy/pathology , Saliva/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...